Sibiman Biomedical Technology

Sibiman Biomedical Technology is a China-based biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Headquartered in Suzhou's BioBAY, the company leverages a proprietary mRNA platform and lipid nanoparticle (LNP) delivery systems to address infectious diseases and oncology. Its lead program, SBM-001, is an mRNA vaccine candidate targeting COVID-19 that has entered clinical trials. Sibiman aims to establish a full-chain capability from sequence design to large-scale GMP manufacturing. The company is backed by prominent venture capital firms like GL Ventures and focuses on high-efficiency, low-toxicity delivery solutions.